{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.9","value":"269.75"},{"groupId":"OG001","spread":"37.2","value":"593.47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"The maximum observed plasma concentration of romidepsin (Cmax) obtained directly from the observed concentration versus time data","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Romidepsin 9mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle","id":"OG000","title":"Phase 1: Cohort 1: Romidepsin 9mg/m^2"},{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"OG001","title":"Phase 1: Cohort 2: Romidepsin 14mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) Population includes of all participants who had sufficient concentration-time data to enable the calculation of PK parameters for at least one PK day. For those who were determined to be noncompliant to receiving romidepsin, or for those with incomplete data, a decision to include the analysis was made on a case-by-case basis.","reportingStatus":"POSTED","timeFrame":"Day 1 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration","title":"Maximum Plasma Concentration (Cmax) of Romidepsin in Phase 1","type":"SECONDARY","unitOfMeasure":"ng/mL"}